NO20006357L - Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer - Google Patents

Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer

Info

Publication number
NO20006357L
NO20006357L NO20006357A NO20006357A NO20006357L NO 20006357 L NO20006357 L NO 20006357L NO 20006357 A NO20006357 A NO 20006357A NO 20006357 A NO20006357 A NO 20006357A NO 20006357 L NO20006357 L NO 20006357L
Authority
NO
Norway
Prior art keywords
norcisapride
bulimia
apnea
diseases
treatment
Prior art date
Application number
NO20006357A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006357D0 (no
Inventor
Paul D Rubin
Timothy J Barberich
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO20006357D0 publication Critical patent/NO20006357D0/no
Publication of NO20006357L publication Critical patent/NO20006357L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
NO20006357A 1998-06-15 2000-12-13 Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer NO20006357L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8922498P 1998-06-15 1998-06-15
US12227599P 1999-03-01 1999-03-01
PCT/US1999/013099 WO1999065571A2 (en) 1998-06-15 1999-06-10 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders

Publications (2)

Publication Number Publication Date
NO20006357D0 NO20006357D0 (no) 2000-12-13
NO20006357L true NO20006357L (no) 2001-02-13

Family

ID=26780365

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006357A NO20006357L (no) 1998-06-15 2000-12-13 Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer

Country Status (26)

Country Link
US (4) US6048879A (is)
EP (1) EP1089733B1 (is)
JP (1) JP2002518352A (is)
KR (3) KR20010052739A (is)
CN (1) CN1312717A (is)
AR (1) AR019671A1 (is)
AT (1) ATE291427T1 (is)
AU (1) AU4433399A (is)
BG (1) BG105096A (is)
BR (1) BR9911299A (is)
CA (1) CA2333666A1 (is)
CZ (1) CZ20004737A3 (is)
DE (1) DE69924375T2 (is)
ES (1) ES2237110T3 (is)
HK (1) HK1040058A1 (is)
HU (1) HUP0102203A3 (is)
IL (1) IL140118A0 (is)
IS (1) IS5756A (is)
NO (1) NO20006357L (is)
NZ (3) NZ526943A (is)
PL (1) PL345275A1 (is)
PT (1) PT1089733E (is)
SI (1) SI1089733T1 (is)
SK (1) SK19052000A3 (is)
TR (7) TR200103058T2 (is)
WO (1) WO1999065571A2 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
TR200103759T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
EP1435238A1 (en) * 1999-03-01 2004-07-07 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
JP2002538102A (ja) * 1999-03-01 2002-11-12 セプラコア インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7844338B2 (en) * 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20040172084A1 (en) 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US7803195B2 (en) * 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007098202A2 (en) * 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid based apparatus, system, and method for therapeutic treatment of a patient
US20100198103A1 (en) 2007-10-09 2010-08-05 Imthera Medical, Inc. System and method for neural stimulation
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
BR112012010986A2 (pt) 2009-11-10 2016-04-12 Imthera Medical Inc sistema para estimular um nervo hipoglosso para o controle da posição da língua de um paciente
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
WO2015134747A1 (en) 2014-03-06 2015-09-11 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) * 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4598123A (en) * 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) * 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) * 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU671430B2 (en) * 1991-12-21 1996-08-29 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5407953A (en) * 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
WO1999002496A1 (en) * 1997-07-11 1999-01-21 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Also Published As

Publication number Publication date
TR200103054T2 (tr) 2002-06-21
EP1089733A2 (en) 2001-04-11
TR200103057T2 (tr) 2002-06-21
HK1040058A1 (zh) 2002-05-24
DE69924375D1 (de) 2005-04-28
AU4433399A (en) 2000-01-05
TR200103059T2 (tr) 2002-06-21
AR019671A1 (es) 2002-03-13
KR20060067986A (ko) 2006-06-20
ATE291427T1 (de) 2005-04-15
US6369079B1 (en) 2002-04-09
WO1999065571A2 (en) 1999-12-23
TR200103056T2 (tr) 2002-06-21
KR20010052739A (ko) 2001-06-25
WO1999065571A3 (en) 2000-04-20
NZ508824A (en) 2003-10-31
TR200003708T2 (tr) 2001-06-21
BG105096A (en) 2002-02-28
NO20006357D0 (no) 2000-12-13
BR9911299A (pt) 2001-03-13
DE69924375T2 (de) 2005-08-11
CN1312717A (zh) 2001-09-12
NZ535135A (en) 2006-04-28
HUP0102203A2 (hu) 2001-11-28
IS5756A (is) 2000-12-08
CZ20004737A3 (cs) 2001-10-17
US20020147220A1 (en) 2002-10-10
CA2333666A1 (en) 1999-12-23
ES2237110T3 (es) 2005-07-16
US6048879A (en) 2000-04-11
EP1089733B1 (en) 2005-03-23
IL140118A0 (en) 2002-02-10
PT1089733E (pt) 2005-08-31
US6835740B2 (en) 2004-12-28
US20050154018A1 (en) 2005-07-14
SI1089733T1 (en) 2005-06-30
HUP0102203A3 (en) 2001-12-28
KR20060017570A (ko) 2006-02-23
SK19052000A3 (sk) 2001-06-11
PL345275A1 (en) 2001-12-03
NZ526943A (en) 2004-11-26
TR200103058T2 (tr) 2002-06-21
JP2002518352A (ja) 2002-06-25
TR200103055T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
NO20006357D0 (no) Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer
NO20034430D0 (no) Tiohydantoiner og anvendelse derav for behandling av diatbetes
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO20020567D0 (no) Fremgangsmåte for tillaging og bruk av ozonanriket vann
NO20041203L (no) Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
NO20034437L (no) Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
ID27414A (id) Penghambat-penghambat non-peptidil dari pengikat sel tergantung vla-4 yang bermanfaat dalam pengobatan penyakit-penyakit inflamasi, autoimun dan pernafasan
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20006358L (no) Anvendelse av optisk ren (-)-norcisaprid ved behandling av apné, bulimi og andre sykdommer
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
NO20040659D0 (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
TR200200278T2 (tr) Kalsilitik bileşimler
NO965247D0 (no) Anvendelse av kryssbundet hemoglobin ved behandling av subarakuoidalblödning
NO934311L (no) alfa,omega-diarylalkanderivater, deres fremstilling og anvendelse ved behandling av sirkulasjonssykdommer og psykoser
NO20043614L (no) 2`-halogen-3`,5`-dialkoksyfen-1`-yl-imino-2-imidazolid in-derivater og anvendelse derav for behandling av urin-inkontinens
NO20020751D0 (no) Kjemisk stabiliserte klorittlösninger for behandling av cancer og andre sykdommer
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte